Mitochondrial DNA Variants and Anti-VEGF Therapy in Ovarian Cancer
Author Information
Author(s): Boso Daniele, Piga Ilaria, Trento Chiara, Minuzzo Sonia, Angi Eleonora, Iommarini Luisa, Lazzarini Elisabetta, Caporali Leonardo, Fiorini Claudio, D’Angelo Luigi, De Luise Monica, Kurelac Ivana, Fassan Matteo, Porcelli Anna Maria, Navaglia Filippo, Billato Ilaria, Esposito Giovanni, Gasparre Giuseppe, Romualdi Chiara, Indraccolo Stefano
Primary Institution: UniversitĂ degli Studi di Padova
Hypothesis
Do pathogenic mitochondrial DNA variants influence the response to anti-VEGF therapy in ovarian cancer?
Conclusion
Pathogenic mitochondrial DNA variants may serve as biomarkers for improved survival in ovarian cancer patients treated with anti-VEGF therapy.
Supporting Evidence
- Pathogenic mtDNA variants were found in 95% of the ovarian cancer PDX models studied.
- PDXs with homoplasmic mtDNA variants showed improved survival when treated with anti-VEGF therapy.
- Functional analyses indicated that mtDNA variants affected mitochondrial respiration and glucose metabolism.
Takeaway
Some changes in the DNA of mitochondria can help doctors understand how well a treatment works for ovarian cancer.
Methodology
The study involved genetic analysis of mitochondrial DNA variants in ovarian cancer patient-derived xenografts and their impact on treatment response.
Potential Biases
Potential bias in the selection of PDX models and their representativeness of the human disease.
Limitations
The study is based on preclinical models, and results may not directly translate to human patients.
Participant Demographics
Ovarian cancer patients from whom the PDX models were derived.
Statistical Information
P-Value
0.0476
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website